Gonadorelin

Gonadorelin is the synthetic decapeptide form of gonadotropin-releasing hormone (GnRH), the master upstream regulator of the entire hypothalamic-pituitary-gonadal (HPG) axis. Endogenous GnRH is a decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) produced by a population of approximately 1,000–2,000 specialised neurons in the hypothalamus (GnRH neurons, also called LHRH neurons) that are distributed across the preoptic area and the mediobasal hypothalamus. These neurons function as the final common output of the hypothalamic reproductive system, integrating inputs from multiple upstream systems — including kisspeptin neurons (the pulse generator), steroid hormone feedback, metabolic signals (leptin, ghrelin, insulin), stress signals (CRH, cortisol), and environmental cues (light-dark cycles) — and converting them into the pulsatile GnRH release pattern that drives the pituitary's cyclic production of LH (luteinising hormone) and FSH (follicle-stimulating hormone).

The pulsatile release of GnRH — occurring approximately every 60–120 minutes in adult men and varying in frequency across the menstrual cycle in women — is not merely a delivery mechanism but a fundamentally important signalling feature. The pituitary gonadotroph cells (which produce LH and FSH) respond specifically to pulsatile GnRH with sustained LH and FSH production. When GnRH is delivered continuously or at too high a frequency, gonadotroph GNRH1R (GnRH receptor 1) undergoes desensitisation and downregulation, and the pituitary paradoxically reduces LH and FSH production — leading to profound hypogonadism. This is precisely the pharmacological mechanism exploited in long-acting GnRH agonist drugs (leuprolide, goserelin, triptorelin) for prostate cancer treatment: continuous GnRH receptor stimulation suppresses the entire HPG axis, achieving castrate-level testosterone. Synthetic gonadorelin (the pulsatile form of exogenous GnRH) must therefore be administered in a pulsatile, non-continuous manner to maintain rather than suppress the HPG axis — a critical practical consideration for all research and clinical protocols.

The most significant current clinical application of gonadorelin in men is as an adjunct to testosterone replacement therapy (TRT) to maintain testicular function and fertility. Exogenous testosterone, when administered at doses sufficient to maintain normal serum testosterone levels, suppresses the HPG axis via negative feedback: high circulating testosterone signals the hypothalamus and pituitary to reduce GnRH and LH output respectively. Chronically suppressed LH results in Leydig cell atrophy (the testosterone-producing cells in the testes), reduction in testicular size, and critically, a profound reduction in intratesticular testosterone levels. While serum testosterone may be in the normal range in a man on TRT, intratesticular testosterone falls to near-zero without endogenous LH stimulation — and intratesticular testosterone at high local concentrations (normally 25–100x serum concentrations inside the testes) is absolutely required for normal spermatogenesis, even when systemic testosterone is adequate. Men on TRT without testicular support become infertile due to this mechanism.

Historically, hCG (human chorionic gonadotropin) — which binds directly to LH receptors on testicular Leydig cells with high affinity and a long half-life of approximately 48 hours — has been the standard co-treatment to prevent testicular atrophy and maintain fertility in men on TRT. hCG mimics LH's action on Leydig cells to stimulate intratesticular testosterone production, directly bypassing the suppressed hypothalamic-pituitary axis. However, following a 2020 FDA regulatory action that reclassified hCG as a biologic and removed many compounded hCG preparations from the market, access to hCG at reasonable cost for TRT co-administration became challenging in the US. This regulatory change created significant clinical demand for alternatives — and gonadorelin emerged as the most pharmacologically logical and accessible option.

Gonadorelin, unlike hCG, does not directly activate LH receptors in the testes. Instead, it activates GnRH receptors on pituitary gonadotroph cells, stimulating them to produce LH (and FSH) which then signal the testes. When administered at small doses subcutaneously 2–3 times per week — mimicking a physiologically pulsatile GnRH signal — gonadorelin partially counteracts the TRT-induced suppression of pituitary LH production, maintaining at least some endogenous LH secretion and therefore some intratesticular testosterone production and spermatogenesis. This approach is considered by many endocrinologists to be more physiologically elegant than hCG because: it preserves hypothalamic-pituitary signalling rather than bypassing it entirely; it maintains FSH secretion (hCG stimulates LH receptors only, not FSH production — gonadorelin stimulates both LH and FSH from the pituitary); and FSH is essential for Sertoli cell function and spermatogenesis in a way that hCG cannot replicate.

Clinical monitoring during gonadorelin use in TRT protocols should include LH, FSH, and testosterone levels (both total and free), along with testicular examination to assess volume preservation. Some clinicians also use seminal analysis periodically to verify maintained spermatogenesis in men with fertility goals. The dose of gonadorelin that produces adequate LH stimulation to preserve testicular function while avoiding excessive LH surges that might interfere with TRT dosing is an individual variable that should be adjusted based on measured LH and testosterone responses.